TAVR at 7 Years Shows Strong Trial Results but Alarming Real-World Mortality
Midterm TAVR data reveal a stark gap: trials show 73%+ valve survival, but real-world registries show 45%+ mortality by 7 years.
Summary
Transcatheter aortic valve replacement (TAVR) — a minimally invasive procedure for severe aortic valve disease — shows reassuring durability in clinical trials at 7 years, but real-world registry data tell a starkly different story. The PARTNER 3 trial found comparable valve survival and low reintervention rates between TAVR and surgery in low-risk patients. However, real-world registries showed 45% mortality by 7 years among TAVR patients, rising above 50% in VA system data. Experts caution that trial populations are carefully screened and exclude frail patients, making direct comparisons to everyday clinical practice misleading. The gap raises urgent questions about patient selection, long-term outcomes, and whether 10-year trial data will be sufficient to guide treatment decisions for younger, healthier patients considering this procedure.
Detailed Summary
Transcatheter aortic valve replacement (TAVR) has become a widely used treatment for severe aortic stenosis — a narrowing of the heart's main outflow valve — and its long-term performance is now under intense scrutiny as midterm data mature.
The PARTNER 3 trial's 7-year results offered reassurance. In low-risk patients randomized to TAVR using the Sapien 3 valve versus open-heart surgery, outcomes were statistically equivalent: 73.4% of TAVR patients versus 74.8% of surgical patients were alive and free of valve failure, and reintervention rates were nearly identical at roughly 6%. These results, published simultaneously in JAMA Cardiology, suggest durable valve performance in controlled trial settings.
However, real-world registry data paint a troubling contrast. Among low-risk TAVR recipients in a national registry, 45.1% had died by 7 years — even among patients aged 65–74, mortality reached 19.1%. Data from Veterans Affairs hospitals showed deaths exceeding 50% by 7 years for a different TAVR platform. These figures dwarf the mortality seen in comparable surgical valve cohorts, where 10-year survival rates approached 93% in recent data.
Experts at the New York Valves conference were candid about the disconnect. Session moderator Martin Leon, MD, emphasized that trial populations are highly selective — excluding frail individuals and other high-risk subgroups common in everyday practice. This means "low risk" in a trial is not equivalent to "low risk" in a cardiology clinic, fundamentally undermining direct comparisons.
For health-conscious adults and clinicians, these findings underscore the importance of patient selection when considering TAVR versus surgical options, particularly for younger patients expected to outlive their prosthetic valve. The data also highlight a broader issue in medicine: randomized trial results may overestimate real-world benefit when trial populations don't reflect the broader patient population. Longer follow-up and better registry-to-trial alignment are urgently needed.
Key Findings
- PARTNER 3 trial: 73.4% of TAVR patients alive and valve-failure-free at 7 years, matching surgical outcomes.
- Real-world registry: 45.1% of low-risk TAVR patients died within 7 years — far exceeding trial mortality rates.
- Even youngest TAVR patients (ages 65–74) faced 19.1% mortality in real-world data by 7 years.
- VA system registry showed over 50% mortality at 7 years for a self-expandable TAVR platform.
- Surgical valve (Resilia) 10-year data showed 93% survival in a similar age group, widening the outcome gap.
Methodology
This is a meeting coverage news report from MedPage Today summarizing presentations at the 2026 New York Valves conference. Evidence draws from the 7-year PARTNER 3 randomized controlled trial (published in JAMA Cardiology) and two real-world registry analyses, lending moderate-to-high credibility. No primary data tables were included in the article.
Study Limitations
The article is a conference report and does not include full methodology, patient demographics, or statistical adjustments for registry analyses. Real-world and trial populations differ substantially, limiting direct comparison. Primary sources (JAMA Cardiology publication and registry papers) should be consulted for complete data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: